Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - February 6, 2025) - Novo Nordisk A/S (NYSE: ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo’s Phase 3 CagriSema Study on Obesity According to the complaint, during the class ...

Since the Novo Nordisk (CSE:NOVOb) share price peaked in June last year ... following the announcement of trial results for their next-generation weight loss drug, CagriSema. On Friday, the stock, ...

Novo Nordisk scored a much-needed win on Friday ... data on a highly touted experimental Novo weight-loss shot called CagriSema fell far short of the expectations the company had set.

Novo Nordisk announced ... loss over 68 weeks for CagriSema, and 20.7% weight loss for a 72-week regimen of semaglutide 7.2 milligram (mg). On Friday, however, Novo Nordisk announced top-line ...

Shares in Novo Nordisk rose as much as 13 per cent on ... dramatically after disappointing results from late stage trials of CagriSema, another weight loss treatment, while this month the shares ...

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little//File Photo · Reuters / Reuters The company ...